IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | $30.00 | Hold → Buy | D. Boral Capital |
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
D. Boral Capital upgraded CERo Therapeutics from Hold to Buy and set a new price target of $30.00
Live Leadership Updates
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO. Mr. Ehrlich commented, "I believe that CERo presents multiple, significant opportunities to make an impact on the market and benefit a significant patient population with both sound science and an experienced team of professionals to drive successful execution.
This live feed shows all institutional transactions in real time.
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13D - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
3/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
Fastest customizable press release news feed in the world
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, announces that Chris Ehrlich, Chief Executive Officer will participate in a stem cell therapy panel titled, "A Space That is Ready to Have its Day," at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City. The panel will be moderated by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. Date: October 22, 2025 Time: 1:30pm ET
Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published article, asserts it is not for sale and is not currently actively seeking partnerships as it continues dose finding clinical activities for CER-1236 SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces it has concluded the first cohort of its Phase 1 CER-1236 clinical trial focused on patients w
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO, Calif, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, today announced that it has dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid leukemia (AML). Per protocol, three patients are planned at this lowest dose level, and enrollment of the third subject may complete the initial cohort pending the outcome of protocol-d
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the Company received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111. The patent that will issue will provide the Company with both composition of matter protection for CER-1
Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has administered a second dose in the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML). The multi-dose intensification has been authorized by the study's Instituti
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program SOUTH SAN FRANSCISCO, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company's lead investigational compound, CER-1236 for Acute Myeloid Leukemia (AML). This designation is in addition to the existi
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML). The patient was dosed at the Sarah Cannon Research Institute (SCRI) at Colorado B
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial's Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly. CERo CMO Robert Sikorski MD., PhD. noted, "The first patien
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo's Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying
SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 per share (the "Common Stock"). The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 13, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") as of the opening of trad